Gilead’s Phase III Trial Halt Raises Questions About Magrolimab’s Value

Gilead halted the Phase III ENHANCE trial of magrolimab in high-risk MDS after a futility analysis • Source: Shutterstock

More from Clinical Trials

More from R&D